Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Hohenstein, B.
155  Ergebnisse:
Personensuche X
?
1

Novel insights into the management of German patients with ..:

Laufs, U ; Birkenfeld, A L ; Fraass, U...
European Heart Journal.  42 (2021)  Supplement_1 - p. , 2021
Link: https://doi.org/10.1093/..
 
?
2

The German Lipoprotein Apheresis Registry (GLAR) – more tha..:

Schettler, V.J.J. ; Peter, C. ; Zimmermann, T....
Atherosclerosis.  331 (2021)  - p. e21 , 2021
Link: https://doi.org/10.1016/..
 
?
3

Immunglobulin- und komplementvermittelte glomeruläre Erkran..:

Hohenstein, B. ; Hugo, C.
Der Nephrologe.  15 (2020)  6 - p. 356-362 , 2020
Link: https://doi.org/10.1007/..
 
?
4

Membranoproliferative Glomerulonephritis und C3‑Glomerulopa..:

Hohenstein, B. ; Amann, K. ; Menne, J.
Der Internist.  60 (2019)  5 - p. 458-467 , 2019
Link: https://doi.org/10.1007/..
 
?
5

Lipoprotein apheresis is an optimal therapeutic option to r..:

Scientific Board of GLAR for the German Apheresis Working Group ; Schettler, V. J. J. ; Neumann, C. L....
Clinical Research in Cardiology Supplements.  14 (2019)  S1 - p. 33-38 , 2019
Link: https://doi.org/10.1007/..
 
?
6

Nierenersatztherapie im 21. Jahrhundert – eine deutsche Per..:

Weinreich, T. ; Hohenstein, B.
Der Nephrologe.  13 (2018)  4 - p. 273-276 , 2018
Link: https://doi.org/10.1007/..
 
?
7

Treatment-related and health-related quality of life in lip..:

De Gucht, V. ; Cromm, K. ; Vogt, A....
Journal of Clinical Lipidology.  12 (2018)  5 - p. 1225-1233 , 2018
Link: https://doi.org/10.1016/..
 
?
8

Therapeutische Apherese am Beispiel der Lipoproteinapherese:

Schettler, V. J. J. ; Hohenstein, B.
Der Nephrologe.  12 (2017)  3 - p. 211-222 , 2017
Link: https://doi.org/10.1007/..
 
?
9

Dysregulation of the CD4 + T cells lineage differentiation ..:

Papin, J. ; Brennand, A. ; Arbore, G....
Atherosclerosis Supplements.  30 (2017)  - p. 238-245 , 2017
Link: https://doi.org/10.1016/..
 
?
10

Kinetics of Lipoprotein(a) in patients undergoing weekly li..:

Tselmin, S. ; Müller, G. ; Schatz, U....
Atherosclerosis Supplements.  30 (2017)  - p. 209-216 , 2017
Link: https://doi.org/10.1016/..
 
?
11

Most significant reduction of cardiovascular events in pati..:

Schatz, U. ; Tselmin, S. ; Müller, G....
Atherosclerosis Supplements.  30 (2017)  - p. 246-252 , 2017
Link: https://doi.org/10.1016/..
 
?
12

Comparing the efficacy of three techniques to reduce isoagg..:

Parmentier, S.P. ; Rosenkranz, E. ; Schirutschke, H....
Atherosclerosis Supplements.  30 (2017)  - p. 253-256 , 2017
Link: https://doi.org/10.1016/..
 
?
13

Lipoprotein apheresis influences monocyte subpopulations:

Jellinghaus, S. ; Reich, C. ; Schatz, U....
Atherosclerosis Supplements.  30 (2017)  - p. 108-114 , 2017
Link: https://doi.org/10.1016/..
 
?
14

Monitoring of complement activation biomarkers and eculizum..:

Wehling, C ; Amon, O ; Bommer, M...
Clinical and Experimental Immunology.  187 (2016)  2 - p. 304-315 , 2016
Link: https://doi.org/10.1111/..
 
?
15

Glomerulonephritis: C3G, MPGN und andere seltene Formen:

Hohenstein, B. ; Hugo, C.
Der Nephrologe.  11 (2015)  2 - p. 116-123 , 2015
Link: https://doi.org/10.1007/..
 
1-15